In this issue:
National GP guidance on breast density – BreastScreen Australia
Metastatic breast cancer: First national prevalence estimates
Radiotherapy de-escalation: SUPREMO trial publication highlighted by TROG
New Zealand: Pharmac decision could enable faster anti-HER2 delivery
PBS listing: capivasertib (Truqap) from 1 October 2025
FDA approval – Trastuzumab deruxtecan (Enhertu) + pertuzumab as 1L HER2+ metastatic standard option
Neo-N (TNBC) update: Blood tests to tailor therapy
Tucatinib (Tukysa) maintenance signal in HER2+ metastatic disease
UQ research: New antibody concept targeting ROR1
Oral SERD giredestrant (adjuvant ER+):Recurrence-risk reduction reported
Conferences, Workshops, CPD
Research Review Publications
Please login below to download this issue (PDF)